Search

Displaying results 2881 - 2890 of 4207 in total
  1. Drug

    Doxylamine

    go.drugbank.com/drugs/DB00366
    ApprovedInvestigationalVet approved

    Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism.

  2. Drug

    Methdilazine

    go.drugbank.com/drugs/DB00902
    Approved

    Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.

  3. Drug

    Ultevursen

    go.drugbank.com/drugs/DB17835
    Investigational

    It was developed by ProQR Therapeutics and is being investigated for the treatment of retinitis pigmentosa.

  4. Drug

    Collagen-polyvinylpyrrolidone

    go.drugbank.com/drugs/DB16525
    Investigational

    It is characterized by antifibrotic, fibrolytic, and immunomodulatory properties[A227733].

  5. Drug

    Topiroxostat

    go.drugbank.com/drugs/DB01685
    Investigational

    Topiroxostat and its metabolites are shown to be unaffected by renal complications, thus may be effective in patients with chronic kidney diseases [A19657].

  6. Drug

    Alfacalcidol

    go.drugbank.com/drugs/DB01436
    ApprovedInvestigationalNutraceutical

    Alfacaldisol is activated by the enzyme 25-hydroxylase in the liver to mediate its effects in the body, or most importantly, the kidneys and bones.

  7. Drug

    Ioversol

    go.drugbank.com/drugs/DB09134
    ApprovedInvestigational

    [L41780] Ioversol was approved by the FDA in 1989 and is currently indicated for computed tomographic (CT) imaging and contrast enhancement in peripheral arteriography, coronary arteriography, and left

  8. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by

  9. Drug

    AICA ribonucleotide

    go.drugbank.com/drugs/DB01700
    Investigational

    of tissues by changing the physical composition of muscle. … The drug was first used in the 1980s as a method to preserve blood flow to the heart during surgery and is currently of interest as a potential treatment for diabetes by increasing the metabolic activity

  10. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. It was first approved for use in the United States in November 2019 under the br...

    Categories: Phosphotransferases (Alcohol Group Acceptor)